The management of children with static encephalopathies with motor system involvement (cerebral palsy) has long been a difficult problem for physicians. Physical and occupational therapy may offer many benefits but clearly cannot address the underlying abnormalities of movement that exist in these patients. Medical management before the introduction of dantrolene and baclofen was more often harmful than helpful because of the sedative effects and tolerance of the drugs used.l Surgical approaches have focused on tendon lengthening but now would include injections of botulinum toxin (quasi surgical), selective dorsal root section, and intrathecal baclofen infusion. Dantrolene unfortunately appears too toxic for longterm use, and so we are left with baclofen as the most effective drug in spasticity. Baclofen decreases the abnormal sensitivity of the disinhibited spinal segment, the chief characteristic of spasticity. Unfortunately, baclofen is not effective in all patients and, in some patients for whom it is effective, produces intolerable side effects at the doses necessary. Dr Albright has presented a clear and concise review of the use of intrathecal baclofen, a technique that promises to allow the delivery of higher concentrations of the drug to the spinal cord with substantially lower concentrations of the drug in the blood.2 This will make the drug applicable to some patients who could not tolerate it with oral administration. Questions that remain, however, include: How does the use of intrathecal baclofen rank with the other possible therapies, including selective dorsal root section and botulinum toxin, for spasticity in patients with cerebral palsy? Why do some children with obvious hypertonia not respond to baclofen? Which children are the best candidates for this therapy? All of these approaches are predicated on the idea that some patients with cerebral palsy have adequate voluntary motor control but are hindered functionally by the degree of increased tone present (a concept that has not been definitively established). 3 3 Baclofen works as a y-aminobutyric acid agonist throughout the central nervous system but most importantly at the spinal segmental level. The currently popular model of spasticity is that the abnormalities are primarily due to the increased reflex sensitivity at the segmental level of the spinal cord. Reflex sensitivity is modulated by a complex interaction of suprasegmental inputs from the brain stem, basal ganglia, cerebellum, motor strip, and other structures. From the clinical standpoint, spasticity is manifested as increased tone and deep tendon reflexes. Muscle tone is usually measured clinically as the resistance to passive movement of an extremity and can be increased without a corresponding increase in reflex activity (hypertonia). Reflex hyperexcitability is demonstrated by producing a sudden stretch on the muscle tendon, inducing a response from the flower-spray end organ, which, transmitted to the spinal segment via the sensory loop of the reflex, produces an exaggerated response due to abnormal spread of the incoming stimulus. This abnormal spread is in turn due to the diminished inhibition of the spinal segment. There may be increased reflex sensitivity without increased tone. Furthermore, tone is also determined by the resting rate of discharge of the anterior hom cell of the motor unit. This resting rate of anterior horn cell discharge is influenced, but not entirely determined, by the sensitivity of the reflex arc and is also determined by supraspinal inputs. Thus, in a patient with athetoid cerebral palsy there may be strikingly increased tone without a correspondingly severe increase in reflex sensitivity but that nevertheless results in a profound motor handicap. This explains why individuals with the dystonic forms of cerebral palsy are not very responsive to drugs (baclofen) and procedures that primarily decrease spasticity by decreasing the sensitivity of the reflex arc (selective dorsal root section). In practice, the situation is complicated by the fact that most patients with cerebral palsy with what Dr Albright calls &dquo;cerebral spasticity&dquo; have some degree of tone abnormality that is not related to reflex arc sensitivity. In these patients, the predominant abnormality may be spasticity recognizable as spastic diplegia, but there may also be an element of tone abnormality that will not diminish with relief of the hyperreflexia. It might seem that this would be easily distinguished by knowledgeable examin-ers ; however, at least 40% of the patients referred to our clinic for consideration of selective dorsal root section for relief of spasticity turn out to have dystonia related to supraspinal inputs rather than reflex abnormality. 4 4 There are two major indications for the use of intrathecal baclofen. The first is in patients with spastic diplegia or quadriplegia who are ambulatory, with or without external aids, but who appear to use their spasticity to aid their gait. These patients often have questionable strength and have been known to lose the ability to ambulate if tone is suddenly diminished via selective dorsal root section. The goal of therapy in these patients is to improve the facility of ambulation. Second, baclofen is used for the reduction of tone in nonambulatory patients with severe spasticity, with the goal of facilitation of nursing care. 2 Assuming that a patient with spastic diplegia has marginal strength, lacks significant dystonia, and wishes to be considered for some sort of therapy to improve the ease of ambulation, the options would include oral baclofen, which might well accomplish the desired goals without resorting to more heroic measures. If the patient is not able to tolerate oral baclofen (possibly because of persistent drowsiness), the remaining options would consist of intrathecal baclofen and selective dorsal root section. Botulinum toxin would not be a likely choice because it decreases tone primarily by decreasing strength, and strength is one of our concerns in such a patient.5 If the intrathecal baclofen screening test suggests that tone can be decreased without substantially weakening the patient, one may conclude that the implantation of a baclofen infusion pump would likely be effective. However, selective dorsal root section also decreases tone without decreasing strength and is more or less permanent. Furthermore, selective dorsal root section has a morbidity rate considerably less than that of the baclofen pump and would be considerably cheaper in the long run. 2,6 It appears that intrathecal baclofen is most helpful in allowing the patient to experience the effect of decreased tone without the permanence of the selective dorsal root section. Once it is determined that the patient can benefit by the reduction in tone, the long-term use of intrathecal baclofen, with its ongoing costs and a 20% to 50% morbidity, moves down the list of therapeutic options.
In the patient with severe spasticity for whom the goal is primarily to improve the ease of nursing care, the use of procedures that decrease strength may be appropriate. Accordingly, botulinum toxin injections for temporary help and tendon release for more permanent relief become therapeutic options. 3, 5, 7 This clinical situation is also one of the primary indications for selective dorsal root section.7 I have little doubt that intrathecal baclofen would accomplish the therapeutic goal and would constitute another option in most of these patients. However, the cost, the morbidity, and the need for continuing pump and catheter maintenance makes intrathecal baclofen less attractive for long-term maintenance than other options. Improvements in the technology and our understanding of the range of clinical situations in which intrathecal baclofen might be useful will certainly change our view of this procedure in the future, but for now there are a limited number of situations in which this is the preferred therapeutic modality.
Decreased muscle tone, the outcome measure in these cerebral palsy patients, has been shown with both selective dorsal root section and intrathecal baclofen infusion. The limiting factor in the functional movement of most of these patients, however, is the impairment of voluntary motor control, not the presence of spasticity. This is probably the explanation for the fact that although selective dorsal root section results in a demonstrable decrease in tone and facilitates movement, there is almost never a gain of a new functional skill after such a procedure.8 Currently, the initial evaluation of a patient with cerebral palsy for one of the available therapeutic options does not address, in any objective fashion, the integrity of the suprasegmental motor control or the relative importance of suprasegmental inputs in the production of the abnormal tone experienced by the patient.
Until we learn how to separate and measure these various inputs, the choice of one procedure over another is necessarily based on subjective criteria and therefore heavily influenced by the bias of the physician in charge.
